NCT00053391View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2007

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

recombinant CD40-ligand

BIOLOGICAL

therapeutic autologous dendritic cells

Trial Locations (1)

D-91052

Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen, Erlangen

All Listed Sponsors
lead

University Hospital Erlangen

OTHER

NCT00053391 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter